--- title: "Selank | PepTracker Pro" description: "A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Selank", "description": "A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.", "url": "https://peptrackerpro.com/peptides/selank", "lastReviewed": "2026-05-08", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Selank", "item": "https://peptrackerpro.com/peptides/selank" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching non-benzodiazepine anxiolytics?", "acceptedAnswer": { "@type": "Answer", "text": "Selank is a research peptide studied in preclinical models. A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." } }, { "@type": "Question", "name": "Those interested in nootropic peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Selank is a research peptide studied in preclinical models. A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." } }, { "@type": "Question", "name": "Individuals exploring immune-modulating compounds?", "acceptedAnswer": { "@type": "Answer", "text": "Selank is a research peptide studied in preclinical models. A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Selank **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Selank Medium Evidence A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. Aliases TP-7 +1 more Evidence Medium Evidence Last Updated 2026-05-08 Reading Time 2 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Evidence Snapshot](#evidence-snapshot) 4. [Commonly Discussed Benefits](#benefits) 5. [Safety & Cautions](#safety) 6. [Comparisons](#comparisons) 7. [Calculator Tools](#calculator) 8. [Citations](#citations) ## What It Is Selank is a heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a synthetic analog of the immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for stability. It has been studied for anxiolytic, nootropic, and immunomodulatory effects. In 2026, laboratory programs are examining how Selank interacts at the receptor level within the BDNF-TrkB and GABAergic signaling systems, with improved analytical instrumentation making preclinical research more precise and reproducible. Advances in nasal and transdermal delivery mechanisms have also improved bioavailability studies. Selank is commonly studied alongside Semax in cognitive peptide research stacks. It is registered as an anxiolytic in Russia but has no FDA approval and is not currently scheduled for PCAC review in the July 2026 sessions. Also known as: TP-7, Selanc ## Regulatory Status Category 1 — Bulk Compounding Returned to Category 1 compounding eligibility under FDA's February 2026 reclassification. May be compounded by 503A/503B pharmacies under physician prescription. Effective: February 2026 [View FDA Source](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding) ## Evidence Snapshot Medium Evidence Low Medium High ## Commonly Discussed Benefits [Anxiety Relief](/benefits/anxiety-relief)[Mood](/benefits/mood)[Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Immune Support](/benefits/immune-support) Researching Selank ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=selank) ## Safety & Cautions - Approved in Russia but not FDA-approved in the US - Most research published in Russian-language journals - Long-term Western clinical data limited - Discuss with a healthcare provider ## Comparisons See how Selank compares to related peptides: [Selank vs DSIP](/compare/selank-vs-dsip) [Selank vs P21](/compare/selank-vs-p21) [Selank vs Semax](/compare/selank-vs-semax) [Selank vs Trontinemab](/compare/selank-vs-trontinemab) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Zozulya AA. et al. — Selank (TP-7): neuropsychotropic properties. Bull Exp Biol Med. 2008 [PubMed](https://pubmed.ncbi.nlm.nih.gov/) 2. \[2\] Addiction Recovery Peptides 2026 Update — RealPeptides [PubMed](https://www.realpeptides.co/addiction-recovery-peptides-2026-update/) ### Keep researching in the app - Log Selank to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=selank) [Browse more peptides](/peptides) ## Related Peptides ### DSIP Low Evidence A neuropeptide studied for its role in sleep regulation and stress modulation. [Sleep](/benefits/sleep)[Mood](/benefits/mood)[Anxiety Relief](/benefits/anxiety-relief)[Pain Relief](/benefits/pain-relief) [View Details](/peptides/dsip) [\+ Compare](/compare?select=dsip)[](https://app.peptrackerpro.com/?add=dsip) ### P21 Medium Evidence An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[brain-health](/benefits/brain-health)[memory](/benefits/memory) [View Details](/peptides/p21) [\+ Compare](/compare?select=p21)[](https://app.peptrackerpro.com/?add=p21) ### Semax Medium Evidence A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Mood](/benefits/mood)[Recovery](/benefits/recovery) [View Details](/peptides/semax) [\+ Compare](/compare?select=semax)[](https://app.peptrackerpro.com/?add=semax) ### Trontinemab Medium Evidence An investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. [cognitive-health](/benefits/cognitive-health)[Neuroprotection](/benefits/neuroprotection)[amyloid-clearance](/benefits/amyloid-clearance)[alzheimers (investigational)]() [View Details](/peptides/trontinemab) [\+ Compare](/compare?select=trontinemab)[](https://app.peptrackerpro.com/?add=trontinemab) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.